NEW YORK, June 1, 2011 /PRNewswire/ -- Investor Uprising (www.investoruprising.com) has released "A Guide to BiotechInvesting," a four-page, definitive guide to the best biotech Exchange Traded Funds (ETFs) and mutual funds, which is available free to registered users of the Website.
(Logo: http://photos.prnewswire.com/prnh/20110411/NY80781LOGO-a )
"Biotech has been roaring forward, and not a lot of investors are aware of how to gain exposure to the market," says R. Scott Raynovich, editor-in-chief, Investor Uprising. "Biotech ETFs are a good play in an appealing investment sector with relatively low correlation to macro-economic problems."
Some biotech funds identified in the report are up more than 100% over the last five years, with less volatility than the Nasdaq Index. This report tells you why, and how to tell the funds apart. The report explains the components of the various biotech ETFs and which should be sought for either large-cap or mid-cap investments. The report compares the leading biotech funds and ETFs with leading technology ETFs.
The mutual funds and ETFs tracked by the report include the T. Rowe Price Health Sciences Fund (PRHSX), Fidelity Select Biotechnology fund (FBIOX), BlackRock Health Sciences Ops Inv A (SHSAX), Vanguard Healthcare ETF (VHT), First Trust NYSE Arca Biotech Index (NYSE: FBT), iShares Nasdaq Biotechnology Index (Nasdaq: IBB), and the SPDR S&P Biotech ETF (NYSE: XBI).
The report is the second in a series of free ground-breaking reports published on Investor Uprising and available to registered readers for free. Readers can register for the site here.
About Investor Uprising
Investor Uprising is the individual investor's no-nonsense community for accessing business trends and investment strategies. Combining expert market commentary, fundamental analysis and on-the-ground reporting, Investor Uprising helps the reader find the best investment opportunities in global markets. Sponsored by PR Newswire and operated by UBM plc, Investor Uprising's community of contributors will reach millions of potential business readers around the world.
About PR Newswire
PR Newswire (www.prnewswire.com) is the premier global provider of multimedia platforms that enable marketers, corporate communicators, sustainability officers, and public affairs and investor relations officers to leverage content to engage with all their key audiences. Having pioneered the commercial news distribution industry 56 years ago, PR Newswire today provides end-to-end solutions to produce, optimize, and target content – from rich media to online video to multimedia – and then distribute content and measure results across traditional, digital, mobile, and social channels. Combining the world's largest multi-channel, multi-cultural content distribution and optimization network with comprehensive workflow tools and platforms, PR Newswire enables the world's enterprises to engage opportunity everywhere it exists. PR Newswire serves tens of thousands of clients from offices in the Americas, Europe, Middle East, Africa, and the Asia-Pacific region, and is a UBM plc company.
DeusM (www.deusm.com) is headquartered in New York City. Its name is an abbreviation of Deus Ex Machina, a term derived from classical drama that describes the moment that a god is introduced into a play to resolve the entanglements of the plot. The company specializes in the use of proprietary high-value content and Web 2.0 technology to attract highly qualified audiences to its communities – and keep them engaged there. DeusM is a UBM plc company.
Media Contact:Rachel MeranusVice President, Marketing and CommunicationsPR Newswire+1.201.360.6776Rachel.Meranus@prnewswire.com
Meryl SerouyaMarketing & Communications AssociatePR Newswire+1.201.360-6009Meryl.Serouya@prnewswire.com
SOURCE Investor Uprising
Subscribe to our Free Newsletters!
Learn the basics about diabetes and how to bring it under control with turmeric, an highly ...